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Running title: Development of Allergy Diary Companion app 
 
 
Summary 
Background: Allergic rhinitis (AR) management has changed in recent years following the switch 
from the concept of disease severity to the concept of  disease control, publication of the AR clinical 
decision support system (CDSS) and development of mobile-health (m-health) tools for patients (e.g. 
Allergy Diary). The Allergy Diary Companion app for health care providers is currently being 
developed and will be launched in 2018. It incorporates the AR CDSS to provide evidence based 
treatment recommendations, linking all key stakeholders in AR management.  
Objective: To produce an electronic version of the AR CDSS (e-CDSS) for incorporation into the 
Allergy Diary Companion, to describe the app interfaces used to collect information necessary to 
inform the e-CDSS and to summarize some key features of the Allergy Diary companion.  
Methods: The steps involved in producing the e-CDSS and Incorporating it into the Allergy Diary 
Companion were (i) generation of treatment management scenarios; (ii) expert consensus on 
treatment recommendations; (iii) generation of electronic decisional algorithms to describe all AR 
CDSS scenarios; (iv) digitization of these algorithms to form the e-CDSS; and (v) embedding the e-
CDSS into the app to permit easy user e-CDSS interfacing. 
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Results: Key experts in the AR field agreed on the AR CDSS approach to AR management, and on 
specific treatment recommendations provided by Allergy Diary Companion. Based on this consensus, 
decision processes were developed and programmed into the Allergy Diary Companion using 
Titanium Appcelerator (Javascript) for IOS tablets. To our knowledge this is the first time the 
development of any m-health tool has been described in this transparent and detailed way, 
providing confidence, not only in the app, but also in the provided management recommendations.   
Conclusion: The Allergy Diary Companion for providers, provides guideline and expert-endorsed AR 
management recommendations. [MASK paper No 32] 
 
Introduction 
The aim of allergic rhinitis (AR) management is to achieve control of the disease and its symptoms [1, 
2], and is a dynamic process. Control can fluctuate over time influenced by many factors, including 
AR phenotype (i.e. intermittent or persistent AR), environmental exposure and current treatment. 
Therefore, the tool used to measure disease control must be simple, suitable for everyday use and 
sensitive to change. A simple visual analogue scale (VAS) has been recommended as the language for 
assessing AR control [2-4]. It has recently been converted to electronic format and included in a free 
mobile app for patients - Allergy Diary – as part of MASK (Mobile Airways Sentinel network) [5-8]. 
The Allergy Diary aims to empower patients to self-manage their AR [5, 6]. The use of self-
management and information & communication technology may hold the key to chronic disease 
management, and provides useful objective data for physicians. 
The VAS has also been Incorporated into an AR clinical decision support system (CDSS), a new type 
of disease management tool [2].  A CDSS is a health information technology system, based on the 
best evidence and algorithms, designed to provide physicians, and other health care providers, with 
clinical decision support (i.e. assistance with clinical decision-making tasks). It is an important tool 
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for precision medicine [9, 10]. Within the AR CDSS, the VAS is used to assess AR control and to assist 
in making management decisions, assisting patients and health care providers to jointly determine 
AR treatment and its step-up or step-down strategy depending on the status of AR control [2].  
 
The next step is to integrate the AR CDSS into an app for providers called Allergy Diary Companion, 
by producing an electronic version of it (e-CDSS). The Allergy Diary Companion app is designed for 
use during a patient-physician consultation. The e-CDSS will effectively be the ‘brain’ of the app, 
providing guideline-directed AR management recommendations in response to 4 inputs: VAS score, 
Allergic Rhinitis & its Impact on Asthma (ARIA)-defined AR phenotype, allergen exposure and AR 
treatment history. This article describes the production of the e-CDSS from the paper version [2]  for 
incorporation into the Allergy Diary Companion. Expert consensus on AR-CDSS recommendations, as 
well as the production of decision process to describe this consensus and programme the app are 
also described. Finally, description of the various interfaces used by the app to collect information 
necessary to inform the e-CDSS and key features of Allergy Diary Companion are summarized. 
 
Methods 
From the AR CDSS to the e-CDSS 
Figure 1 outlines the six steps involved in the transformation of the paper AR-CDSS to the e-CDSS 
(Suppl. Figure 1A & B) [2]. 
AR treatment scenario identification 
Step 1: Major scenarios on AR management approach  
Thirteen major scenarios were identified from the AR CDSS (S-Table 1). These scenarios incorporated 
VAS score cut-offs, ARIA-defined AR phenotype (i.e. intermittent or persistent AR) and AR treatment, 
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and provided an AR management approach (i.e. when to initiate treatment, continue, step-up and 
step-down treatment). T0 represents no treatment. For the purpose of these scenarios, AR 
treatments were coded as:  
 T1: Non-sedating H1-antihistamines (oral, intranasal, intraocular), leukotriene receptor 
antagonists (LTRA), cromones (intranasal or intraocular) 
 T2: Intranasal corticosteroid (INCS) 
 T3: INCS + azelastine (AZE) 
 T4: Oral corticosteroids (as add on to local treatment) 
 T5: Consider referral to an allergist and allergen immunotherapy (AIT) 
The AR CDSS is an algorithm for the acute symptomatic treatment of AR. Recommendations on the 
benefits and use of AIT may be found elsewhere [11]. 
Step 2: Specific AR treatment recommendations 
From these 13 major scenarios, 34 detailed scenarios were [2]. Inputs considered included disease 
phenotype (i.e. intermittent/persistent), allergen exposure, VAS score and current treatment and 
specific AR management recommendations were provided (S-Tables 2, 3, 4 & 5). 
Key opinion leader consensus on AR CDSS treatment recommendations 
Step 3: Survey of experts 
These 34 detailed scenarios were incorporated into a survey that was delivered by an online service, 
Survey Monkey (www.surveymonkey.com), and sent to 70 experts on AR and ARIA members from 
23 countries, in order to achieve consensus and improve robustness of the AR CDSS algorithm. 
Experts were selected for their expertise (i.e. general practice, allergy, ENT, respiratory medicine, 
pharmacy, public health) with a global representation. We aimed at a 50% response rate. The survey 
was divided into 4 parts: (i) general approach to AR treatment (i.e. when to initiate, continue, step 
up or step down treatment; n= 8 questions; S-Table 2); (ii) treatment step up (i.e. what treatment to 
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step up to considering current treatment; n= 11 questions; S-Table 3); (iii) treatment step down (i.e. 
what treatment to step down to considering current treatment; n = 12 questions; S-Table 4); and (iv) 
treatment initiation (i.e. what treatment to start with, considering VAS score and AR phenotype; n= 
3 questions; S-Table 5). Experts indicated their level of agreement for each of the 34 presented 
scenarios on a VAS ranging from 0 mm (strongly disagree) to 100 mm (strongly agree). A response 
was returned by 35 experts (response rate: 50%) from the USA and Canada (n=5), Europe (n=26), 
South America (n=2) and Australia (n=2).  
Individual scores for each of the 34 scenarios were tabulated, averaged and categorized in the 
classical way: survey VAS score 0-25 mm (poor agreement); 25-49 mm (fair agreement); 50-74 mm 
(good agreement); 75-100 mm (excellent agreement) (S-Figure 2A). Excellent expert consensus was 
achieved for all step up scenarios except scenarios 11 (survey VAS score: 64 mm, 13 (survey VAS 
score: 64 mm), and 14 (survey VAS score: 64 mm) which all dealt with step up from T3 (S-Table 3; S-
Figure 2A).  Excellent expert consensus was also achieved for all step down scenarios except 
scenarios 20 (survey VAS score: 74 mm) and 21 (survey VAS score: 66 mm) which dealt with step 
down from T3 or T2, respectively (S-Table 4; S-Figure 2A). The reasons for these lower consensus 
scores and resolution of these issues is provided in the online supplement. 
Step 4: Scenario modification and summary of findings 
An email was sent to all experts who provided a survey VAS score <50 mm for any scenario to (i) 
understand the reason for disagreement and (ii) achieve consensus on a resolution. Experts were 
permitted to change their original survey VAS scores based on the results of this discussion process 
(these changes are shown in red font in S-Figure 2B). Expert agreement increased to a VAS score >75 
for all scenarios that were considered a second time. Details of expert comments on the scenarios, 
and the response and resolution are provided in the online supplement. 
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Step 5: Digital specifications of AR CDSS (all scenarios and modifications) 
The next step was to digitally specify the agreed scenarios to generate a series of digital rules used 
to programme the Allergy Diary Companion (Ecole des Mines, Ales). The first task was to define a set 
of representative scenarios with experts of the domain, taking into account all possible parameters 
(e.g. VAS, ongoing treatment, type of patient). Then, scenarios were translated into a graphical 
representation, providing an algorithm, which allowed the recommendations to be automatically 
defined (Figure 2 A-D). The algorithm was validated in several ways: (i) review with experts, (ii) 
review of recommendations and (iii) transformation of the algorithm into a state machine (i.e. a 
model representing the state cycle of a patient.) The process enabled verification that the patient 
state may evolve, depending on adequate value of VAS, and according to all possible treatment 
transitions (i.e. from “no treatment” to “under treatment”, staying “under treatment” and come 
back to “no treatment”). These verifications ensured that all possible situations were taken into 
account in a systematic way. 
Step 6: Finally, a total of 77 scenarios (all possible scenarios) were programmed into the Allergy 
Diary Companion.   The app was programmed and designed by Peercode, Netherlands, using the 
digital specifications above (including expert treatment recommendations), ensuring consideration 
of each possible input into the app. It was developed in titanium appcelerator (Javascript) for tablets 
on the IOS platform, and is easily translated and modified. Usability of the app and reliability of the 
treatment recommendations it provides has been checked by Peercode and further validation is 
currently ongoing prior to launch. The app requires no internet function after download. 
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Results 
Summary of survey results 
Mean scores for each question were calculated to show the level of consensus for each of the 34 AR 
CDSS scenarios (Table 1 and S-Figure 3 A-D). Experts endorsed the AR CDSS approach, with good 
agreement achieved on step-up and step-down treatment recommendations. In summary: 
 AR treatment should be stepped up for treated AR patients with a VAS score ≥ 5/10 cm. 
 For patients with VAS score ≥2 to <5/10 cm, treatment should be continued for patients with 
intermittent AR (IAR) and continued or stepped up for those with persistent AR (PER). 
 Treatment should be stepped down for patients with a VAS score <2/10 cm. 
 When step up treatment is recommended, patients on T1 should be stepped up to T2 OR T3 
 When step up treatment is recommended, patients on T2 should be stepped up to T3. 
 Short course oral corticosteroids (i.e. T4) may be added here if necessary. 
 Patients should be referred (e.g. to ENT or allergy specialists) if VAS score remains ≥ 5/10 cm 
or if there is a need for oral corticosteroids. 
 When step up treatment is recommended, patients on multiple therapies should be stepped 
up to T3, and T4 added on (short course to minimise side effects and only if necessary) 
 Stepping down treatment was essentially the same in reverse, with the proviso that patients 
with nasal congestion should be stepped down to an INCS-containing regimen in preference 
to T1 (albeit many patients will self-medicate and stop treatment).** 
 Treatment step-up and step-down strategies remain the same irrespective of AIT status.* 
*: Does not consider the indication of AIT 
**: Modified after expert consensus 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Digital specification of the e-CDSS modules 
In order to make a treatment recommendation, the CDSS within the Allergy Diary Companion must 
be ‘fed’ with information. We have described this information as modules (Table 2) with each of 
modules 1, 2 and 3 providing the input necessary for module 4 (i.e. e-CDSS) 
Module 1 (VAS score): During physician consultation or pharmacist visit, patients generate a VAS 
score using their finger and the touch screen functionality of an iPad, allowing selection of VAS score 
from 0 to 10 cm (inclusive). For the purpose of the e-CDSS, VAS scores are categorized as ≥5/10 cm 
(uncontrolled AR), ≥2 to <5/10 cm (partly-controlled AR) and <2/10 cm (well-controlled AR) (Table 
2), the same as those cut-offs used by Allergy Diary These cut-offs were selected based on clinical 
studies in both asthma and rhinitis [12-17]. 
Module 2 (treatment classification system): The purpose of this module is to define the class(es) of 
current AR medications used by patients. A simple alpha-numeric system was used for the e-CDSS, 
with treatments classified from T0 (no treatment) up to T5 (consider referral and AIT) (Table 2).  
Module 3 (patient information): Patients input this information into the Allergy Diary Companion 
during physician consultation. The information gathered (or computed) includes: 
 Specific AR medication currently used  
 AR phenotype (i.e. IAR or PER) 
o AR phenotype is classified according to duration of medication use (Questions 3a 
and 4a, Table 2) or duration of symptoms for untreated patients (Questions 3b and 
4b, Table 2) 
 Allergen exposure status  
o Information on what constitutes an allergen is provided for patients 
AR medication(s) are selected from a scrolled list of all over the counter or prescribed medications 
available in each country (Question 2a, Table 2). Multiple medication selections are permitted.  For 
each medication class selected, a corresponding treatment code is assigned by the system. Exposure 
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to allergen is assessed using a simple true or false algorithm (Table 2). S-Figure 4 shows the 
organogram of the sequence of questions that patients answer in Module 3. At any step, the patient 
can go back to a previous question to correct his/her answer, or cancel the survey answer. No 
personal information is collected. 
 
Module 4 (e-CDSS specifications): The e-CDSS uses data obtained from the other modules to deliver 
a recommendation corresponding to the most appropriate treatment. Table 2 summarizes how this 
information is gathered, the input used by the e-CDSS to make a decision and the variables used 
(online supplement). Information from each of these modules is used to produce treatment 
recommendations. The decision processes underlying treatment recommendations are shown in 
Figure 2 (A-D). Four decision processes were developed to cover 4 scenarios: (i) the patient is not 
currently on any AR medication (Figure 2A), (ii) the patient has well-controlled AR (i.e. VAS score <2 
cm; Figure 2B), (iii) the patient has partly-controlled AR (i.e. VAS score ≥2 to <5 cm; Figure 2C), (iv) 
the patient has uncontrolled AR (i.e. VAS score ≥ 5 cm; Figure 2D). 
 
Interfaces specifications  
Collecting information 
Allergy Diary Companion screen interfaces for collecting VAS score for the e-CDSS is shown in Figure 
3A. The VAS question is ‘overall how much are your allergic symptoms bothering you today?’ and is 
identical to that used in the Allergy Diary for patients, ensuring that both physicians and patients are 
speaking the same language of AR control. This allows for inter-connectivity between applications, 
consistency of AR control assessment and computation. The Allergy Diary Companion screen 
Interfaces for collecting information on AR medication use, AR phenotype and allergen exposure 
(Module 3) are shown in S-Figure 5. 
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Summarizing information 
The following information is summarized by Allergy Diary Companion for providers (Figure 3B): 
 AR disease control status message: ‘Your patient has [well-, partly- or un-] controlled allergic 
rhinitis.’ 
 Current VAS score of the patient: this is expressed as a positive integer to one decimal place. 
AR control is categorized according to this VAS score, and colour coded in the same way as 
for the Allergy Diary – well-controlled AR: green (VAS score <2 cm); partly controlled AR: 
yellow (VAS score ≥2 to <5 cm) and uncontrolled AR: orange: (VAS score ≥5 cm) (Figure 3B). 
 AR phenotype: This is categorized as either ‘intermittent’ or ‘persistent’ depending on 
duration of treatment (or symptoms). 
 Allergen exposure: summarized as either ‘yes’ or ‘no’ 
 Treatment: List of currently taken AR treatments. 
 
Treatment recommendation 
A treatment recommendation is then provided based on this information, and using the rules as 
outlined in the e-CDSS (Figures 2A-2D) and summarized in Table 1. Treatment recommendations are 
in the format: Recommendation – approach – specific treatment recommendation. For the example 
shown in Figure 3B the recommendation is to step up treatment, as the patient has a VAS score 
≥5/10 cm, has IAR (with allergen exposure) and is currently treated (with AIT and FP – i.e. T5 + T2) - 
see Table 1 scenario 1. The recommended treatment option is to continue the AIT course and step 
up symptomatic treatment to INCS + AZE (i.e. step up from T5 + T2 = T5 + T3) – see Table 1 scenario 
18. By clicking on ‘INCS + AZE’ the treatment listed is ‘Dymista’, currently the only medication in this 
class. 
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Discussion 
In this article we describe a 21st century approach to AR management. m-Health refers to the use of 
mobile devices to collect, collate, and assess patient level health data. In this article we focus on 
CDSS and m-health in AR, and describe the process of transforming the recently published AR-CDSS 
[2] into an e-CDSS, and how this e-CDSS was embedded into an m-health tool for providers called 
the Allergy Diary Companion.  
Incorporation of the e-CDSS into the Allergy Diary Companion was achieved in a systematic and 
collaborative way, by (i) generating treatment management scenarios, (ii) obtaining expert 
consensus on specific AR CDSS-informed treatment recommendations, allowing for variations in line 
with expert opinion; (iii) generating electronic algorithms to describe all scenarios within the AR 
CDSS; (iv) digitizing these algorithms to form the e-CDSS and finally (v) embedding the e-CDSS into 
the Allergy Diary Companion app to permit easy user interfacing. In this way the Allergy Diary 
Companion serves as a knowledge translation intervention for providers, a dynamic and iterative 
process that induces the synthesis, dissemination, exchange and ethically sound application of 
knowledge to improve health [18], encouraging change in behaviour in keeping with scientific 
evidence. Key experts in the field of AR from all over the world agreed on the AR CDSS approach to 
AR management, and on specific treatment recommendations provided by Allergy Diary Companion 
and informed by VAS score, disease phenotype, allergen exposure and treatment history. To our 
knowledge this is the first time the development of any m-health tool has been described in this 
transparent and detailed way, providing confidence, not only in the app, but also in the treatment 
recommendations it provides.  
The Allergy Diary Companion is essentially a decision aid for providers. Decision aids increase 
knowledge, reduce decisional conflict and have a positive effect on patient-practitioner 
communication [19, 20], and may be particularly effective when incorporated into an e-health tool. 
For example, when providers use handheld computers to access clinical information, their 
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knowledge improves significantly more than peers who use paper resources. Physician adherence to 
guidelines is poor [21] and it is hoped that when guideline recommendations are presented 
electronically, providers may make  safer prescribing decisions and adhere more closely to these 
recommendations vs peers using paper resources [22]. Unfortunately, at the physician level CDSSs 
are rarely used, and the advice is not followed [23], even though use of computerized CDSSs have 
been shown to improve asthma and COPD care [24]. Embedding the AR CDSS into the Allergy Diary 
Companion is expected to increase usage of the AR CDSS, resulting in improved standard of AR care 
in routine clinical practice, both at the physician and pharmacy levels. Indeed CDSSs have already 
proved beneficial at the pharmacy level [25, 26], reducing the frequency of drug-drug interactions 
and preventing inappropriate prescribing and under-prescribing [27]. It should also be noted that 
although a recently conducted Cochrane review provided no evidence that the use of electronic 
health information (EHI) translates into improved clinical practice or patient outcomes, it does 
suggest that when practitioners are provided with EHI and education or training, its use increases 
[28]. It was further noted that for EHI to be applied in patient care, it will be necessary to understand 
why practitioners' are reluctant to apply EHI when treating people, and to determine the most 
effective way(s) to reduce this reluctance [28]. 
 
On the patient side, mobile phone apps to improve allergy and asthma care are part of an ever-
growing number of m-tools available, but their usefulness is still debated and studies have been 
small [29], [30].  However, a large study including 327 individuals with AR or asthma, showed that 
QoL was improved in AR patients and the likelihood of asthma control increased when using an app 
which facilitated communication with physicians and which recorded health status and medication 
compliance [31].  
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A limitation of the Allergy Diary Companion is that it currently relies on the input of information by 
patients themselves. It does not take into account data already recorded by patients in their Allergy 
Diary. In other words, there is a lack of connectivity between m-health tools. One improvement 
could be to upload patient data directly from the Allergy Diary to the Allergy Diary Companion (i.e.  
Module 5; see Figure 4). This step would need serious ethical consideration that are currently being 
discussed.  Personal data protection is a fundamental right in Europe, enshrined in Article 8 of the 
Charter of Fundamental Rights of the European Union, as well as in Article 16(1) of the Treaty on the 
Functioning of the European Union. Guidance already exists on data protection requirements for 
"apps" with Opinion 2/2013 of the Article 29 Working Party of 27 February 2013 on apps on smart 
devices. In the EU, the currently applicable Personal Data Protection Directive is being revised in 
order to better respond to challenges posed by the rapid development of new technologies and 
globalisation while ensuring that individuals retain effective control over their personal data. The 
Allergy Diary Companion app will comply with all local and European directives. Future iterations of 
the Allergy Diary Companion may permit connectivity with pollen, air pollution, meteorologic storm 
warnings and google trends which may influence treatment recommendations. Finally, all Allergy 
Diary Companion app functionally and management advice needs to be validated, and this will be 
done prior to launch. The Allergy Diary Companion app is an ideal tool to assess the benefit of using 
the AR CDSS in a real life setting. The value of this m-health tool is that it allows for variations and 
modifications of the e-CDSS based on real life experience, thus moving from a consensus-based CDSS 
to an evidence-based one. 
 
Other modules which may be used to ‘feed’ the e-CDSS could include identification of those patients 
at risk of allergen exposure by incorporating a pollen alert module (Module 6; Figure 4) and a 
sentinel network module (Module 7; Figure 4). The sentinel network is an early warning system or 
predictor for patients of impending symptoms. A recently obtained H2020 grant (POLLAR: Impact of 
air pollution in asthma and rhinitis) will help to answer this question. This system should also prove 
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useful in predicting asthma control deterioration in those with co-morbid rhinitis. Use of predictive 
algorithms have already been used in home monitoring of asthma and chronic obstructive 
pulmonary disease patients, but with varying degrees of success, mainly due to poor patient 
compliance and poor performance of conventional algorithms for detecting deteriorations [32]. 
These improvements to the system would essentially negate the need for Modules 1 and 3 for those 
users with smart phones. Modules 1 and 3 would remain in the system for those patients who do 
not have smartphone or do not wish to download Allergy Diary.  Finally, a PC-based tool should also 
be developed, enabling physicians to import data, with individual patient consent, to their pc directly 
from the patient’s Allergy Diary, interacting with Allergy Diary Companion, so that data may be 
stored as an electronic file as part of the patient’s notes. 
When developing any new m-health tool, the aim is to achieve a high quality and popular app, which 
will be used enthusiastically and provide benefit to users. This is  a challenging process, and not 
always entirely successful, either due to design issues [33] or at the implementation stage [28, 
34]. Allergy Diary Companion for providers has been designed to be used in conjunction with the 
Allergy Diary for patients as part of MASK (included in the B3 action plan of the European Innovation 
Partnership on Active and Healthy Ageing (EIA on AHA). MASK follows the JA-CHRODIS (Joint Action 
on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle) recommendations for the 
evaluation of Good Practices. This means that it works well, produces good results and is 
recommended as a model [35]. MASK complies with equity (design and implementation), practice 
(e.g. appropriateness of design, SMART objectives), ethical, evaluation, empowerment/participation, 
target population, sustainability, governance and scalability targets [35]. Use of both apps will (i) 
permit patients to screen for allergic disease and monitor AR and asthma control, (ii) assist 
pharmacists in  recommending over the counter medications and prompt referral of patients with 
uncontrolled AR to physicians and (iii) encourage primary care physicians to prescribe appropriate 
treatment, to follow-up in accordance with the AR CDSS and to refer to specialist clinics when 
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appropriate [36].  However, the e-CDSS does not include information on allergic multi-morbidities 
[37]. That will be included at a later stage. 
In conclusion, the Allergy Diary Companion for providers has been designed to provide healthcare 
information to practitioners and researchers, to permit real-time monitoring of disease related data 
and to provide guideline and expert-endorsed AR treatment recommendations. The Allergy Diary 
Companion is currently being finalized and will be launched in 2018. 
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Table 1: KOL consensus opinion and level of agreement for each scenarios of the AR CDSS 
 
 Patient 
VAS 
Phenotype Tx Consensus Level of 
agreement 
Part 1: Approach to treatment 
1 ≥5 IAR or PER Yes Step up 91 
2 ≥2 to <5 IAR Yes Continue 76 
3 <2 IAR Yes Step down 85 
4 ≥2 to <5 PER Yes Continue or step up 88 
5 <2 PER Yes Step down 75 
6 ≥5 IAR No Initiate 97 
7 ≥5 PER No Initiate 98 
8 <5 IAR or PER No Initiate 87 
Part 2: Specific treatment step ups 
 Current Tx Step up Notes  
9 T1 T2 OR T3  91 
10 T2 T3  83 
11 T3 T3 + T4* Consider T5† 66 
12 T1 + T2 T3  Consider T5† 80 
13 T1 + T3 T3 + T4* Consider T5† 68 
14 T2 + T3 T3 +T4 Consider T5† 66 
15 T5 + VAS ≥5 T5 + T2 OR T3  80 
16 T5 + VAS ≥2 to <5 T5 + T1, T2 OR T3 T5 + T2 or T3 if congestion 84 
17 T5 + T1 T5 + T2 OR T3  89 
18 T5 + T2 T5 + T3  86 
19 T5 + T3 Continue Consider referral 86 
Part 3: Specific treatment step downs 
 Current Tx Step down Notes  
20 T3 T2 OR T1 T2 if congestion 78 
21 T2 T1 Continue T2 if congestion 73 
22 T1 Stop NOT exposed to allergen 86 
23 T1 Continue EXPOSED to allergen 84 
24 T1 + T2 T1 OR T2 T2 if congestion 87 
25 T1 + T3 T1 OR T3 T3 if congestion 79 
26 T2 + T3 T2 OR T3  87 
27 T5 + T3 T5 + T1 OR T2 T5 + T2 if congestion 80 
28 T5 + T2 T5 + T1 Continue T5 + T2 if 
congestion 
75 
29 T5 + T1 T5 NOT exposed to allergen 91 
30 T5 + T1 T5 + T1 EXPOSED to allergen 83 
31 T5 T5 Until end of course 97 
Part 4: treatment initiation  
 Patients  Tx Consensus Notes  
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32 IAR; VAS ≥5 No T1, T2 OR T3 T2 or T3 if congestion 83 
33 PER; VAS ≥5 No T2 OR T3  90 
34 IAR or PER VAS <5 No T1, T2 OR T3 T2 or T3 if congestion 87 
VAS: visual analogue scale; Tx: treatment; IAR: intermittent allergic rhinitis; PER: persistent allergic 
rhinitis; T1: anti-histamine (oral, intranasal, eye drops), leukotriene receptor antagonist, or cromones 
(intranasal, eye drops); T2: intranasal corticosteroids (INCS); T3: INCS + azelastine; T4: oral 
corticosteroid; T5: consider referral and allergen-specific immunotherapy. 
* short course (3-7 days); †if VAS score remains ≥5/10 
Level of agreement: VAS≥75: excellent; VAS 50-74: good 
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Table 2: Modules of e-CDSS 
 
 Info Description e-CDSS 
decision or 
input 
e-CDSS 
variable 
M1 VAS (cm) <2: well controlled 
≥2 to <5: partly controlled 
≥5: uncontrolled 
<2 
≥2 to <5 
≥5 
[1..5] 
 
M2 
 
Treatment 
classification 
None T0  
AH/LTRA/cromone T1  
Ti, Tj, Tk, Tl INCS T2 
INCS & AZE T3 
OC T4 
Consider referral & AIT T5 
M3 Patient 
characteristics 
Q1: Do you currently take AR medication? Current med {True/false} 
Q2a: Select medication(s) Scrolled list  
Q3a: How many days/week do you usually 
take your Tx (1-7)? 
 
Week ≥4 &  
day ≥4 
 
{True/false} 
True=PER 
False=IAR 
Q4a: How many consecutive weeks do 
you take it (1-5 or more)? 
Q2b: Is this the first time experiencing 
symptoms? 
First 
experience 
{True/false} 
 
Q3b: How many days/week do they last 
(1-7)? 
 
Week ≥4 &  
day ≥4 
 
{True/false} 
True=PER 
False=IAR 
Q4b: How many consecutive weeks do 
they last (1-5, or more)? 
Q5: Are you currently exposed to 
allergen? 
Yes or don’t 
know 
{True/false} 
True=yes 
False=no 
M4 CDSS Data from M1, M2 and M3   
CDSS: clinical decision support system; VAS: visual analogue scale; AH: anti-histamine (oral, intranasal, 
eye drops); LTRA: leukotriene receptor antagonist; INCS: intranasal corticosteroid; AZE: azelastine; OC: 
oral corticosteroid; AIT: allergen-specific immunotherapy; AR: allergic rhinitis; Tx: treatment; PER: 
persistent AR; IAR: intermittent AR; Ti: current treatment (if multiples Ti=highest medication class); Tj,k,l: 
add on treatments to Ti 
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Figure Legends 
Figure 1: Steps for the development of the ARIA e-CDSS 
MACVIA: Contre les Maladies Chroniques pour un Vieillissement actif; ARIA: Allergic Rhinitis 
and its Impact on Asthma; AR: allergic rhinitis; CDSS: clinical decision support system; VAS: 
visual analogue scale; KOL: key opinion leader. 
Figure 2: Decision processes underlying treatment recommendations for (A) patients not 
currently on any AR medication, (B) patients with well-controlled AR (i.e. VAS score <2), (C) 
patients with partly-controlled AR (i.e. VAS score ≥2 to <5) and (D) patients with 
uncontrolled AR (i.e. VAS score ≥ 5). AR: allergic rhinitis; VAS: visual analogue scale; M1: 
module 1; M2: module 2; M3: module 3; Ti: class of current treatment (in case of 
polypharmacy, Ti = maximum class). Tj, Tk and Tl: medications added to Ti, order of class 
l<k<j<i. T1: anti-histamine (oral, intranasal, eye drops), leukotriene receptor antagonist, 
cromone (intranasal, eye drops); T2: intranasal corticosteroid (INCS); T3: INCS + Azelastine; 
T4 add short course of oral corticosteroids; T5: consider referral and allergen-specific 
immunotherapy 
Figure 3: (A) VAS scale interface of Allergy Diary and Allergy Diary Companion apps and (B) 
Treatment recommendation provided by e-CDSS of the Allergy Diary Companion app, 
including information from Modules 1, 2 and 3. 
Figure 4: Schematic representation of architecture of an improved e-CDSS. M: module; Tx: 
treatment; e-CDSS: electronic clinical decision support system.  
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